Trial · NCT03085485
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Safety of Ivacaftor - Number of Participants With Adverse Events | Ivacaftor | Subject with any AE | 19 | Participants | |
| Safety of Ivacaftor - Number of Participants With Adverse Events | Placebo | Subject with any AE | 6 | Participants | |
| Safety of Ivacaftor - Number of Participants With Adverse Events | Ivacaftor | AE resulting in drug interruption | 7 | Participants | |
| Safety of Ivacaftor - Number of Participants With Adverse Events | Placebo | AE resulting in drug interruption | 3 | Participants | |
| Safety of Ivacaftor - Number of Participants With Adverse Events | Ivacaftor | AE resulting in drug discontinuation | 1 | Participants | |
| Safety of Ivacaftor - Number of Participants With Adverse Events | Placebo | AE resulting in drug discontinuation | 1 | Participants | |
| Safety of Ivacaftor - Number of Participants With Abnormal Serum Chemistry | Ivacaftor | 0 | Participants | ||
| Safety of Ivacaftor - Number of Participants With Abnormal Serum Chemistry | Placebo | 0 | Participants | ||
| Safety of Ivacaftor - Number of Participants With Abnormal Hematology | Ivacaftor | 0 | Participants | ||
| Safety of Ivacaftor - Number of Participants With Abnormal Hematology | Placebo | 0 | Participants | ||
| Safety of Ivacaftor - Number of Participants With Abnormal ECG (Prolonged QT Intervals) | Ivacaftor | 1 | Participants | ||
| Safety of Ivacaftor - Number of Participants With Abnormal ECG (Prolonged QT Intervals) | Placebo | 1 | Participants | ||
| Central CFTR Activity Measured by Mucociliary Clearance (MCC) Percentage Clearance at 60 Mins | Ivacaftor | Screening | 88.4 | Standard Deviation 12 | percentage of clearance |
| Central CFTR Activity Measured by Mucociliary Clearance (MCC) Percentage Clearance at 60 Mins | Placebo | Screening | 86.2 | Standard Deviation 7 | percentage of clearance |
| Central CFTR Activity Measured by Mucociliary Clearance (MCC) Percentage Clearance at 60 Mins | Ivacaftor | Day 84 | 86 | Standard Deviation 17 | percentage of clearance |
| Central CFTR Activity Measured by Mucociliary Clearance (MCC) Percentage Clearance at 60 Mins | Placebo | Day 84 | 80 | Standard Deviation 2 | percentage of clearance |
| Peripheral CFTR Activity Measured by Change in Sweat Chloride | Ivacaftor | 3.9 | Standard Deviation 9.8 | mmol/L | |
| Peripheral CFTR Activity Measured by Change in Sweat Chloride | Placebo | 3.8 | Standard Deviation 12.1 | mmol/L | |
| Indicators of Respiratory Function and COPD Health : Change in FEV1 Predict % | Ivacaftor | 1.5 | Standard Deviation 4.7 | predict percentage | |
| Indicators of Respiratory Function and COPD Health : Change in FEV1 Predict % | Placebo | -0.4 | Standard Deviation 7.6 | predict percentage |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03085485/results